Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Abstract Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible tyrosine kinase inhibitor with structural specificity for the catalytic domain...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Petros D. Grivas, Kathleen C. Day, Andreas Karatsinides, Alyssa Paul, Nazia Shakir, Iya Owainati, Monica Liebert, Lakshmi P. Kunju, Dafydd Thomas, Maha Hussain, Mark L. Day
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: BMC 2013-10-01
Cyfres:Molecular Medicine
Pynciau:
Dacomitinib
Bladder Cancer Xenografts
Non-obese Diabetic/severe Combined Immunodeficiency (NOD/SCID)
Epidermal Growth Factor Receptor (EGFR)
Lapatinib
Mynediad Ar-lein:https://doi.org/10.2119/molmed.2013.00108

Rhyngrwyd

https://doi.org/10.2119/molmed.2013.00108

Eitemau Tebyg